Our research is dedicated to ensuring the safety of medicines at every stage of their development and use. From preclinical studies to post-marketing assessments that monitor real-world effects, we work to refine drug safety profiles and fill knowledge gaps. Through pharmacovigilance and effective risk communication, we aim to detect and prevent adverse reactions, ensuring that patients and healthcare professionals have the information they need for safe and informed use of medications.
Our activities include:
- Preclinical studies to identify a safe dose for humans and establish key safety parameters for clinical monitoring.
- Post-marketing assessment to refine the safety profile of medicines in real-world settings and address evidence gaps from pre-marketing studies.
- Pharmacovigilance monitoring to detect, assess, and prevent adverse drug reactions.
- Effective risk communication to ensure transparency and promote informed decision-making
Progetti
- AIFA - Fondo Regionale di Farmacovigilanza: "COSIsiFA" (Cittadini e Operatori Sanitari sempre informati sul Farmaco) (2025-2030; infarmaco.it).